XML 42 R25.htm IDEA: XBRL DOCUMENT v3.25.1
Collaboration and License Agreements (Tables)
 6 Months Ended
Mar. 31, 2025
Collaboration And License Agreements [Abstract]  
Schedule of Revenue
The following table provides a summary of revenue recognized:
Three Months Ended March 31,Six Months Ended March 31,
2025202420252024
(in thousands)
GSK$3 $— $2,503 $2,685 
Takeda— — — 866 
Sarepta542,706 — 542,706 — 
Total$542,709 $— $545,209 $3,551 
Schedule of Receivables and Contract Liabilities
The following table summarizes the balance of receivables and contract liabilities related to the Company’s
collaboration and license agreements:
March 31, 2025September 30, 2024
(in thousands)
Receivables included in accounts receivable$2,365 $— 
Contract liabilities included in deferred revenue$43,268 $— 
Collaborative Arrangement and Arrangement Other than Collaborative The fixed and estimated variable consideration of $904.9 million was allocated in accordance to the following table:
March 31, 2025
(in thousands)
Upfront payment
$500,000 
Annual fees
250,000 
Equity premium
83,612 
Fixed consideration
$833,612 
Estimated variable consideration
71,243 
Total transaction price
$904,855